Pacer Advisors’s Travere Therapeutics TVTX Stock Holding History

Pacer Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56K	Buy	+986	New	+$43.7K	﹤0.01%	2011
2024 Q3	–	Sell	-1,037	Closed	-$8.52K	–	2699
2024 Q2	$8.52K	Sell	1,037 -1,734	-63%	-$11.7K	﹤0.01%	3575
2024 Q1	$21.4K	Buy	+2,771	New	+$23.4K	﹤0.01%	3431
2021 Q2	–	Sell	-2,293	Closed	-$57K	–	1556
2021 Q1	$57K	Buy	2,293 +744	+48%	+$20.6K	﹤0.01%	1427
2020 Q4	$42K	Sell	1,549 -348	-18%	-$8.13K	﹤0.01%	1433
2020 Q3	$35K	Buy	+1,897	New	+$36.9K	﹤0.01%	1322
2018 Q4	–	Sell	-2,631	Closed	-$76K	–	1014
2018 Q3	$76K	Buy	+2,631	New	+$75.2K	﹤0.01%	1117
2018 Q1	–	Sell	-650	Closed	-$14K	–	1131
2017 Q4	$14K	Buy	+650	New	+$14.9K	﹤0.01%	1123

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pacer Advisors's TVTX Position: Q2 2026 in Review

Pacer Advisors opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 986 shares worth $56K. The stake represents ﹤0.01% of the portfolio and ranks #2011 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in TVTX as recently as Q2 2024.

Pacer Advisors first reported a position in TVTX in Q4 2017 and has held it in 8 quarters since. The position peaked at $76K in Q3 2018. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Pacer Advisors held 986 shares of Travere Therapeutics worth $56K as of Q2 2026.
Travere Therapeutics was a new Pacer Advisors position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2011 holding.
Pacer Advisors first reported a position in Travere Therapeutics in Q4 2017 and has held it in 8 quarters since.
Pacer Advisors's Travere Therapeutics position peaked at $76K in Q3 2018.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.